Results 141 to 150 of about 2,034,530 (343)

Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment

Aging and Cancer, EarlyView.
Melanoma, the deadliest form of skin cancer, increasingly affects older adults. Our study reveals that melanoma induces changes in iron and lipid levels in the bone marrow, impacting immune cell populations and increasing susceptibility to ferroptosis.
Alexis E. Carey, Murilo Ramos Rocha, Cheyenne Palm, Vania Wang, Denys Balandin, Ethan Black, Kevin Y. Zhang, Fan Huang, Daniel J. Zabransky, Yash Chhabra, Mareike Peters, Gabriel Ghiaur, Ashani Weeraratna   +12 more
wiley   +1 more source

The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential

Aging and Cancer, EarlyView.
As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley   +1 more source

1122 Radiotherapy-activated NBTXR3 nanoparticles induce interferon beta secretion by cancer cells [PDF]

, 2022
Jordan Da Silva, Sébastien Paris
openalex   +1 more source

Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells

Circulation, 2004
J. Rehman, D. Traktuev, Jingling Li, Stephanie Merfeld‐Clauss, C. Temm-Grove, Jason E. Bovenkerk, Carrie L. Pell, B. Johnstone, R. Considine, K. March   +9 more
semanticscholar   +1 more source

Natural Products as Geroprotective Modulators in Diabetic Nephropathy: A Mechanistic Framework Integrating Aging Hallmarks and the AMPK–SIRT1–Nrf2 Axis

Aging and Cancer, EarlyView.
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu, Latif Adams, Eunice Ampem‐Danso, Justice Kumi, Abigail Aning, Fatima Hamidu, Mustapha Abdul Mumin Mohammed, Ayuba Nii Darku Ankrah, Seth Kwabena Amponsah   +8 more
wiley   +1 more source

Letter: Levodopa and growth hormone secretion. [PDF]

, 1973
C F Colucci, B D'Alessandro, Antonio Bellastella, R Gasbarro   +3 more
openalex   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Editorial: Tau Propagation Mechanisms: Cell Models, Animal Models, and Beyond

Frontiers in Neuroscience, 2020
Yumiko Motoi, Diane P. Hanger, Masato Hasegawa   +2 more
doaj   +1 more source

Supplementary Figure S10 from Bone Marrow–Derived Gr1⁺ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1 [PDF]

, 2023
Raúl Catena, Nandita Bhattacharya, Tina El Rayes, Suming Wang, Hyejin Choi, Dingcheng Gao, Seongho Ryu, Natasha Joshi, Diane R. Bielenberg, Sharrell B. Lee, Svein A. Haukaas, Karsten Gravdal, Ole J. Halvorsen, Lars A. Akslen, Randolph S. Watnick, Vivek Mittal   +15 more
openalex   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source